GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) » Definitions » ROC %

Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) ROC % : 65.81% (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Tibet Rhodiola Pharmaceutical Holding Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Tibet Rhodiola Pharmaceutical Holding Co's annualized return on capital (ROC %) for the quarter that ended in Dec. 2024 was 65.81%.

As of today (2025-04-07), Tibet Rhodiola Pharmaceutical Holding Co's WACC % is 11.13%. Tibet Rhodiola Pharmaceutical Holding Co's ROC % is 57.13% (calculated using TTM income statement data). Tibet Rhodiola Pharmaceutical Holding Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Tibet Rhodiola Pharmaceutical Holding Co ROC % Historical Data

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Rhodiola Pharmaceutical Holding Co ROC % Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.67 24.11 30.14 61.99 61.45

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.45 64.25 60.74 34.69 65.81

Tibet Rhodiola Pharmaceutical Holding Co ROC % Calculation

Tibet Rhodiola Pharmaceutical Holding Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=1115.627 * ( 1 - 8.25% )/( (1696.676 + 1634.736)/ 2 )
=1023.5877725/1665.706
=61.45 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4587.357 - 672.289 - ( 2375.127 - max(0, 1184.47 - 3402.862+2375.127))
=1696.676

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4747.338 - 487.764 - ( 2624.838 - max(0, 766.571 - 3569.908+2624.838))
=1634.736

Tibet Rhodiola Pharmaceutical Holding Co's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=1132.844 * ( 1 - 2.72% )/( (1714.442 + 1634.736)/ 2 )
=1102.0306432/1674.589
=65.81 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4671.034 - 440.475 - ( 2589.99 - max(0, 976.374 - 3492.491+2589.99))
=1714.442

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4747.338 - 487.764 - ( 2624.838 - max(0, 766.571 - 3569.908+2624.838))
=1634.736

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Tibet Rhodiola Pharmaceutical Holding Co's WACC % is 11.13%. Tibet Rhodiola Pharmaceutical Holding Co's ROC % is 57.13% (calculated using TTM income statement data). Tibet Rhodiola Pharmaceutical Holding Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Tibet Rhodiola Pharmaceutical Holding Co ROC % Related Terms

Thank you for viewing the detailed overview of Tibet Rhodiola Pharmaceutical Holding Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Rhodiola Pharmaceutical Holding Co Business Description

Traded in Other Exchanges
N/A
Address
No. 93, Beijing Middle Road, Tibet Autonomous Region, Lhasa, CHN, 610023
Tibet Rhodiola Pharmaceutical Holding Co is a Chinese company producing biological products and traditional Tibetan medicines.
Executives
Wang Bao Ming senior management
Peng Hui Director
Cao Shu Zhen senior management
Si Qin Director
Ren Bei Chen Supervisors
Liu De Gong Supervisors
Gao Zi Li senior management
Zhou Ming De senior management
Chen Li Ye senior management
Lin Ben Director
Chen Da Bin Director

Tibet Rhodiola Pharmaceutical Holding Co Headlines

No Headlines